This ASX 200 healthcare share just hit a new 52-week high. Here's why

The ASX 200 health imaging company is edging back towards its all-time highs.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Pro Medicus share price just hit fresh 52-week highs
  • The ASX 200 healthcare share announced a $25 million contract with the University of Washington’s UW Medicine health system
  • Planning for the cloud-based rollout will start immediately

S&P/ASX 200 Index (ASX: XJO) healthcare share Pro Medicus Ltd (ASX: PME) is marching higher today, up 1.51% at the time of writing.

That sees the healthcare stock trading for $63.06 per share after hitting $63.35 late this morning, a fresh 52-week high. It's also now less than 4% below the all-time Pro Medicus share price high, reached in August 2021.

four excited doctors with their hands in the air

Image source: Getty Images

What's sending the ASX 200 healthcare share higher?

Investors are rewarding Pro Medicus after the health imaging company announced on Friday that Visage Imaging, its 100% owned United States subsidiary, signed a $25 million, seven-year contract with the University of Washington's UW Medicine health system.

UW Medicine employs 29,000 healthcare professionals, researchers, and educators.

The ASX 200 healthcare share reported UW Medicine will implement its cloud-engineered Visage 7 Enterprise Imaging Platform throughout its network "providing a unified diagnostic imaging platform".

Planning for the cloud-based rollout will start immediately. Pro Medicus expects the first go-lives to commence in the second half of 2023.

Commenting on the contract, Pro Medicus CEO Sam Hupert said:

UW Medicine joins our growing list of Tier 1 academic clients and will provide us with a strong presence in the Northwest region of the United States. With its highly regarded University of Washington School of Medicine, it has the added benefit of exposing Visage to an ever-increasing number of the doctors of tomorrow.

Hupert noted that the contract encompasses all Pro Medicus Visage products.

"Our pipeline remains strong and spans all market segments," he said. "And as has been the case with many of our recent sales, this deal is for our 'full-stack' comprising all three Visage products namely viewer, workflow and archive, a trend we see continuing."

Pro Medicus share price snapshot

As you can see in the chart below, the Pro Medicus share price strongly outperformed over the past 12 months, gaining 40% compared to a 4% gain posted by the ASX 200.

Investors who bought into the ASX 200 healthcare share five years ago will be sitting on some superbly healthy gains of 683%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »